Antimony
LightNews LightNews
antimony96.bsky.social
Antimony
@antimony96.bsky.social
33 followers 37 following 29 posts
backup if twitter actually eats shit
Posts Replies Media Videos
antimony96.bsky.social
However many percs your mom got for selling you was too much
January 18, 2026 at 10:33 PM
Reposted by Antimony
sailorrooscout.bsky.social
The study has been published in Nature Medicine. YES, it is PEER-REVIEWED.
• www.nature.com/articles/s41...

🧪🧵⬇️
KEY TAKEAWAYS •Gastrointestinal cancers- including pancreatic, and colorectal cancers- account for about 26% of all cancers worldwide. • Both pancreatic and colorectal cancers are susceptible to gene mutations called KRAS mutations, which can make these cancers harder to treat. •A new study shows that an 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with colorectal or pancreatic cancer tumors driven by KRAS mutations. •ELI-002 2P targets mutant KRAS proteins using an amphiphile delivery platform, enhancing immune response by directing antigens to lymph nodes. •The Phase I trial showed significant improvements in relapse-free and overall survival, especially in patients with high T-cell responses. •Safety outcomes were favorable, with NO grade 3 or higher adverse events, cytokine release syndrome, or dose-limiting toxicities observed. • If validated in larger trials, KRAS-targeted vaccination could become a new strategy for preventing recurrence in aggressive solid tumors. ABSTRACT Cellular immunity, mediated by tumor antigen-specific CD4+ and CD&+ T cells, has a critical role in the success of cancer immunotherapy by targeting intracellular driver and passenger tumor mutations. We present the final results of the phase 1 AMPLIFY-201 trial, in which patients who completed standard locoregional treatment, with minimal residual mKRAS disease (n=25, 20 pancreatic cancer and 5 colorectal cancer), received monotherapy vaccination with lymph node-targeting ELI-002 2P, including mutant KRAS (KRAS) amphiphile-peptide antigens (G12D, G12R) and amphiphile-adjuvant CpG-7909. At a median follow-up of 19.7 months, efficacy correlated with mKRAS-specific T cell responses above or below a threshold 9.17-fold increase over baseline, with median radiographic relapse-free survival not reached, versus 3.02 months (hazard ratio (HR) = 0.12, P =0.0002) and median overall survival not reached versus 15.98 months (HR= 0.23, P=0.0099). Seventy-one percent of evaluable patients induced both CD4+ and CD&+ subsets, with sustained immunogenicity. Following ELI-002 2P treatment, antigen spreading was observed in 67% of patients, with increased T cells reactive to personalized, tumor antigens absent from the ELI-002 2P vaccine. Therefore, lymph node-targeting amphiphile vaccination induces persistent T cell responses targeting oncogenic driver KRAS mutations, alongside personalized, tumor antigen-specific T cells, which may correlate to clinical outcomes in pancreatic and colorectal cancer. ClinicalTrials.gov registration: NCT04853017. The study was sponsored and funded by Elicio Therapeutics. Extended Data Fig. 1: Study schema.
October 26, 2025 at 4:02 PM
Reposted by Antimony
bencollins.bsky.social
Without further ado, here is the trailer for Jeffrey Epstein: Bad Pedophile.

Against all odds, it will air in select theatres on October 2nd, along with the theatrical debut of Sex House.

Tickets go on sale tomorrow.

And, yes, this is real.
theonion.com The Onion @theonion.com · Sep 25
Forget everything you already know about America's most notorious dead person. Jeffrey Epstein: Bad Pedophile is in select theaters October 2.
September 25, 2025 at 3:23 PM
antimony96.bsky.social
Erm, yikes much?
September 23, 2025 at 5:40 AM
antimony96.bsky.social
I support the destruction of the "state" of Israel. I also think Hasan is kind of annoying.
September 23, 2025 at 5:02 AM
antimony96.bsky.social
September 23, 2025 at 5:00 AM
antimony96.bsky.social
Do you normally talk like that
September 23, 2025 at 4:58 AM